Acoustic wave therapy is over 30 years old and was first used in medicine for the treatment of kidney stones (also known as lithotripsy). Acoustic waves are the standard of care worldwide for stones and bone healing. It is a thoroughly researched technology and poses very low risk when used for the majority of indications majority of indications. TRT’s patented, FDA 510(k) cleared unfocused acoustic waves, known as SoftWaves®, produce both positive and negative (Tensile) forces on cells. Our probe generates waves that affect cells within a two-inch diameter. Though all of the cells in this target area are exposed, only pathologic tissue reacts.
Cells are used to being exposed to many forces, however, the combination of simultaneous positive and negative forces puts shearing forces on the cell membrane. The shearing forces momentarily make the membranes permeable while still keeping the cell intact. During this duration of permeability, certain proteins and, more importantly, small pieces of RNA are ejected from the cell into the surrounding tissue.
Neighboring cells sense this RNA release via cellular receptors known as toll-like receptor 3 (TLR3). These receptors are activated by RNA pieces released when nearby cells are damaged or die. SoftWave® treatment, however, triggers TLR3 without damaging cells but rather by just making cells’ membranes temporarily permeable. SoftWaves fool the body into thinking an injury has occurred, and we initiate the natural biologic process of repair.
Four to eight weeks after patients’ first SoftWave® treatment, we see up to a 400% increase in blood vessels (small, medium, and large). We also see a corresponding increase in permanent blood supply, which helps in fighting infections. Consequently, bacteria counts drop dramatically, and biofilms that protect bacteria colonies are destroyed.